PTGX - プロタゴニスト・セラピュ―ティクス (Protagonist Therapeutics Inc.)

PTGXのニュース

   H.C. Wainwright Stick to Their Buy Rating for Protagonist Therapeutics By Investing.com  2021/03/11 11:16:18 Investing.com
H.C. Wainwright Stick to Their Buy Rating for Protagonist Therapeutics
   Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results  2021/03/03 12:00:00 PR Newswire
NEWARK, Calif., March 3, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), today announced it will host a conference call and webcast on Wednesday, March 10 at 4:30 pm ET/1:30 pm PT to discuss its fourth quarter and full year 2020 financial results. Conference Call and…
   Protagonist Therapeutics to Participate in the H.C. Wainwright Global Life Sciences Conference  2021/03/02 12:00:00 PR Newswire
NEWARK, Calif., March 2, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and will host one-on-one meetings with investors at the upcoming virtual H.C….
   Protagonist Therapeutics to Participate in the SVB Leerink Virtual 10th Annual Global Healthcare Conference  2021/02/16 12:00:00 PR Newswire
NEWARK, Calif., Feb. 16, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at SVB Leerink Virtual 10th Annual Global Healthcare Conference taking place…
   DelveInsight Analysts Expect Beta-Thalassemia Market Size to Expand at a CAGR of 16.3% During the Study Period (2017-2030) in the 6MM  2021/02/08 16:30:00 Benzinga
LAS VEGAS , Feb. 8, 2021 /PRNewswire/ -- DelveInsight's Beta-Thalassemia Market report offers a holistic picture of the market landscape of the Beta Thalassemia key companies, emerging pipeline therapies, Beta-Thalassemia market share occupied by individual therapies, current and forecasted Beta-thal market share in the 6MM (the US, and EU5 (the UK, Germany , France , Italy , and Spain ) for the study period. The report highlights the drivers and constraints shaping the present Beta-Thalassemia Market along with the unmet medical needs that offer opportunities to the key players to explore the underlying potential of the market. Some of the key highlights from the Beta-Thalassemia Market Report: The Beta-Thalassemia market outlook appears to be ruled by the iron-chelating agents . Exjade is the first, once-daily oral iron chelator commercially available to treat chronic transfusional iron overload due to a wide range of underlying anemia. The Beta-Thalassemia market is witnessing an influx of gene therapies and gene-edited cell therapies to eradicate the lifetime burden of the disease.
   H.C. Wainwright Stick to Their Buy Rating for Protagonist Therapeutics By Investing.com  2021/03/11 11:16:18 Investing.com
H.C. Wainwright Stick to Their Buy Rating for Protagonist Therapeutics
   Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results  2021/03/03 12:00:00 PR Newswire
NEWARK, Calif., March 3, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), today announced it will host a conference call and webcast on Wednesday, March 10 at 4:30 pm ET/1:30 pm PT to discuss its fourth quarter and full year 2020 financial results. Conference Call and…
   Protagonist Therapeutics to Participate in the H.C. Wainwright Global Life Sciences Conference  2021/03/02 12:00:00 PR Newswire
NEWARK, Calif., March 2, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and will host one-on-one meetings with investors at the upcoming virtual H.C….
   Protagonist Therapeutics to Participate in the SVB Leerink Virtual 10th Annual Global Healthcare Conference  2021/02/16 12:00:00 PR Newswire
NEWARK, Calif., Feb. 16, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at SVB Leerink Virtual 10th Annual Global Healthcare Conference taking place…
   DelveInsight Analysts Expect Beta-Thalassemia Market Size to Expand at a CAGR of 16.3% During the Study Period (2017-2030) in the 6MM  2021/02/08 16:30:00 Benzinga
LAS VEGAS , Feb. 8, 2021 /PRNewswire/ -- DelveInsight's Beta-Thalassemia Market report offers a holistic picture of the market landscape of the Beta Thalassemia key companies, emerging pipeline therapies, Beta-Thalassemia market share occupied by individual therapies, current and forecasted Beta-thal market share in the 6MM (the US, and EU5 (the UK, Germany , France , Italy , and Spain ) for the study period. The report highlights the drivers and constraints shaping the present Beta-Thalassemia Market along with the unmet medical needs that offer opportunities to the key players to explore the underlying potential of the market. Some of the key highlights from the Beta-Thalassemia Market Report: The Beta-Thalassemia market outlook appears to be ruled by the iron-chelating agents . Exjade is the first, once-daily oral iron chelator commercially available to treat chronic transfusional iron overload due to a wide range of underlying anemia. The Beta-Thalassemia market is witnessing an influx of gene therapies and gene-edited cell therapies to eradicate the lifetime burden of the disease.
   H.C. Wainwright Stick to Their Buy Rating for Protagonist Therapeutics By Investing.com  2021/03/11 11:16:18 Investing.com
H.C. Wainwright Stick to Their Buy Rating for Protagonist Therapeutics
   Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results  2021/03/03 12:00:00 PR Newswire
NEWARK, Calif., March 3, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), today announced it will host a conference call and webcast on Wednesday, March 10 at 4:30 pm ET/1:30 pm PT to discuss its fourth quarter and full year 2020 financial results. Conference Call and…
   Protagonist Therapeutics to Participate in the H.C. Wainwright Global Life Sciences Conference  2021/03/02 12:00:00 PR Newswire
NEWARK, Calif., March 2, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and will host one-on-one meetings with investors at the upcoming virtual H.C….
   Protagonist Therapeutics to Participate in the SVB Leerink Virtual 10th Annual Global Healthcare Conference  2021/02/16 12:00:00 PR Newswire
NEWARK, Calif., Feb. 16, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at SVB Leerink Virtual 10th Annual Global Healthcare Conference taking place…
   DelveInsight Analysts Expect Beta-Thalassemia Market Size to Expand at a CAGR of 16.3% During the Study Period (2017-2030) in the 6MM  2021/02/08 16:30:00 Benzinga
LAS VEGAS , Feb. 8, 2021 /PRNewswire/ -- DelveInsight's Beta-Thalassemia Market report offers a holistic picture of the market landscape of the Beta Thalassemia key companies, emerging pipeline therapies, Beta-Thalassemia market share occupied by individual therapies, current and forecasted Beta-thal market share in the 6MM (the US, and EU5 (the UK, Germany , France , Italy , and Spain ) for the study period. The report highlights the drivers and constraints shaping the present Beta-Thalassemia Market along with the unmet medical needs that offer opportunities to the key players to explore the underlying potential of the market. Some of the key highlights from the Beta-Thalassemia Market Report: The Beta-Thalassemia market outlook appears to be ruled by the iron-chelating agents . Exjade is the first, once-daily oral iron chelator commercially available to treat chronic transfusional iron overload due to a wide range of underlying anemia. The Beta-Thalassemia market is witnessing an influx of gene therapies and gene-edited cell therapies to eradicate the lifetime burden of the disease.

calendar